Researcher Spotlight: David Qualls, MD Memorial Sloan Kettering Cancer Center Immunotherapies in lymphoma aim to activate the patient’s own immune system to help target and destroy lymphoma cells. While effective, the impact of these types of therapies is often hampered…
Researcher Spotlight: Paola Ghione, MD MEMORIAL SLOAN KETTERING CANCER CENTER Lymphomas are a highly heterogeneous set of diseases, and while many people will do well with treatment, there are subsets of patients whose cancer does not respond or relapses quickly…
Researcher Spotlight: Dai Chihara, MD UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER Phase I trials are the first step in transitioning new drugs from the bench to the clinic. These trials are intended to evaluate the safety and tolerability of…
Researcher Spotlight: Hans-Guido Wendel, MD Memorial Sloan Kettering Cancer Center Mutations in epigenetic regulators of gene expression are common in follicular lymphoma (FL), which result in altered expression of hundreds of genes. Throughcollaborative efforts with clinical and research leaders at…
Researcher Spotlight: David Scott, MBCHB, PhD BC Cancer The disease course for follicular lymphoma (FL) is highly variable, and while many patients respond to treatment, some may experience relapse or evolution of disease into a more aggressive form of lymphoma.…
Researcher Spotlight: Abner Louissaint, MD, PhD Massachussetts GEneral Hospital Follicular lymphoma (FL) is unique among lymphomas in that there are many interactions between tumor cells and the healthy immune cells in their environment. Although it’s known that this communication is…
Researcher Spotlight: Todd Fehniger, MD, PhD washington university school of medicine Natural killer (NK) cells are a type of immune cell that fight infections and cancer cells. Using advanced techniques for single-cell analysis, Dr. Fehniger’s LRF research aims to study…
Researcher Spotlight: Stephen Ansell, MD, PhD mayo clinic, rochester In addition to lymphoma B cells, a variety of other immune cells are found in the lymph nodes of patients with follicular lymphoma (FL), including diverse populations of T cells. Dr.…
Researcher Spotlight: Ran Xu, PhD DANA FARBER CANCER INSTITUTE Many patients with mantle cell lymphoma (MCL) achieve complete remission with novel chimeric antigen receptor (CAR) T cell therapies, but some cancer cells remain that may eventually lead to relapse. Using…
Researcher Spotlight: David Russler-Germain, MD, PhD Washington University School of Medicine Although genetic mutations can drive the development of cancer, many healthy white blood cells intentionally alter their DNA to generate diverse antibody responses to infections. Dysregulation of this activity…